The International Myeloma Working Group (IMWG) was formed by the International Myeloma Foundation (IMF) to encourage dialogue and collaboration among the world’s leading myeloma experts. IMWG members are divided into workgroups, which work together to examine such important topics as frontline therapy, MRD assessment, the role of transplant, genetic risk stratification, renal impairment, and treatments on the horizon.
IMWG Mission and History
The mission of the International Myeloma Working Group (IMWG) is to conduct basic, clinical, and translational research in a collaborative manner to improve outcomes in myeloma and to provide scientifically valid and critically appraised consensus opinions on the diagnosis and treatment of myeloma and related disorders.
To fulfill its mission, the IMWG’s more than 200 members worldwide are divided into workgroups. Researchers in each group examine such important topics as frontline therapy, MRD assessment, the role of transplant, genetic risk stratification, renal impairment, and how best to incorporate new treatments.
As the result of its many publications in scientific journals and guidelines for myeloma treatment and diagnosis, the IMWG has grown in influence and stature. An IMWG paper co-written by Dr. S. Vincent Rajkumar and IMF Chairman Dr. Brian G.M. Durie on the updated response criteria for myeloma has become one of the most cited papers in myeloma.
The IMWG has its roots in the IMF’s Scientific Advisory Board, which was formed in 1995. Recognizing the need for a more intimate event that encouraged dialog among experts, the IMF organized the first IMWG Summit in 2010 in Barcelona, Spain. Since then, IMWG members have gathered annually in London (2011), Vienna (2012), Stockholm (2013), Milan (2014), Vienna (2015), Copenhagen (2016), Madrid (2017), Stockholm (2018), and Amsterdam (2019).
Creating, supporting, and hosting the important work of the IMWG and its members is a critical element of the International Myeloma Foundation’s mission to expand myeloma research and to educate multiple myeloma patients around the world.